← Evidence map

ArticleCurrent oncology (Toronto, Ont.)2026

Berubicin Substituted for Cytarabine in a MATRix-Based Regimen for Isolated Central Nervous System Lymphoma: A Five-Patient Case Series from the BER-PUM Study.

Sławomir Milczarek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Berubicin Substituted for Cytarabine in a MATRix-Based Regimen for Isolated Central Nervous System Lymphoma: A Five-Patient Case Series from the BER-PUM Study. | OpenQuestion